Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy

TY - JOUR

T1 - Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy

AU - Schmiegelow, Kjeld

AU - Müller, Klaus

AU - Mogensen, Signe Sloth

AU - Mogensen, Pernille Rudebeck

AU - Wolthers, Benjamin Ole

AU - Stoltze, Ulrik Kristoffer

AU - Tuckuviene, Ruta

AU - Frandsen, Thomas

PY - 2017

Y1 - 2017

N2 - During chemotherapy for childhood acute lymphoblastic leukemia, all organs can be affected by severe acute side effects, the most common being opportunistic infections, mucositis, central or peripheral neuropathy (or both), bone toxicities (including osteonecrosis), thromboembolism, sinusoidal obstruction syndrome, endocrinopathies (especially steroid-induced adrenal insufficiency and hyperglycemia), high-dose methotrexate-induced nephrotoxicity, asparaginase-associated hypersensitivity, pancreatitis, and hyperlipidemia. Few of the non-infectious acute toxicities are associated with clinically useful risk factors, and across study groups there has been wide diversity in toxicity definitions, capture strategies, and reporting, thus hampering meaningful comparisons of toxicity incidences for different leukemia protocols. Since treatment of acute lymphoblastic leukemia now yields 5-year overall survival rates above 90%, there is a need for strategies for assessing the burden of toxicities in the overall evaluation of anti-leukemic therapy programs.

AB - During chemotherapy for childhood acute lymphoblastic leukemia, all organs can be affected by severe acute side effects, the most common being opportunistic infections, mucositis, central or peripheral neuropathy (or both), bone toxicities (including osteonecrosis), thromboembolism, sinusoidal obstruction syndrome, endocrinopathies (especially steroid-induced adrenal insufficiency and hyperglycemia), high-dose methotrexate-induced nephrotoxicity, asparaginase-associated hypersensitivity, pancreatitis, and hyperlipidemia. Few of the non-infectious acute toxicities are associated with clinically useful risk factors, and across study groups there has been wide diversity in toxicity definitions, capture strategies, and reporting, thus hampering meaningful comparisons of toxicity incidences for different leukemia protocols. Since treatment of acute lymphoblastic leukemia now yields 5-year overall survival rates above 90%, there is a need for strategies for assessing the burden of toxicities in the overall evaluation of anti-leukemic therapy programs.

U2 - 10.12688/f1000research.10768.1

DO - 10.12688/f1000research.10768.1

M3 - Review

C2 - 28413626

SN - 2046-1402

VL - 6

JO - F1000Research

JF - F1000Research

M1 - 444

ER -